N/A
Completed N=1,264
Assessment of Chronic Obstructive Pulmonary Disease (COPD) Therapy From the Physicians Perspective Using Tiotropium as an Example
Pulmonary Disease, Chronic Obstructive
Source: ClinicalTrials.gov NCT01036763 ↗
Enrolled (actual)
1,264
Serious AEs
0.4%
Results posted
Mar 2012
Primary outcomePrimary: Success of Treatment With Tiotropium According to Physician's Assessment — 620; 618; 452; 412 Participants
Summary
Documentation of successful therapy with tiotropium (Spiriva Respimat; Spiriva (tiotropium 18 mcg capsules)) in COPD patients requiring long-acting bronchodilators: description of the most important outcome parameters according to the physicians assessment to determine the success of therapy. Such data are not yet available.
Also collection of physicians assessments and patients assessments of efficacy and tolerability of Spiriva Respimat, Spiriva (tiotropium 18 mcg capsules).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Success of Treatment With Tiotropium According to Physician's Assessment |
620; 618; 452; 412; 235; 106 | — |
| PRIMARY Assessment of Efficacy According to Physician |
342; 645; 172; 44; 27; 34 | — |
| PRIMARY Assessment of Tolerability According to Physician |
601; 572; 35; 9; 13; 34 | — |
| PRIMARY Assessment of Efficacy According to Patient |
339; 620; 169; 55; 35; 46 | — |
| PRIMARY Assessment of Tolerability According to Patient |
564; 567; 54; 14; 17; 48 | — |
| SECONDARY Physician's Global Evaluation at Visit 1 |
8; 294; 755; 206; 1 | — |
| SECONDARY Physician's Global Evaluation at Visit 2 |
61; 737; 407; 31; 28 | — |
Eligibility Criteria
Inclusion criteria COPD patients requiring long-acting bronchodilators according to approved Summary of Product Characteristics (SPC) and guidelines
Exclusion criteria Patients cannot be recruited if any of the general or specific contraindications listed in the Patient information leaflet or the Summary of Product Characteristics applies.
Data sourced from ClinicalTrials.gov (NCT01036763). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.